Effect of Allogenic Ex-vivo Expanded Bone Marrow Derived Mesenchymal Stem Cells on Knee Osteoarthritis – A Randomized Controlled Trial

2023-503974-19-00 Phase II and Phase III (Integrated) Not authorised

Status Not authorised · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Phase II and Phase III (Integrated)
Status Not authorised
Participants planned 112
Countries 1
Sites 1

Osteoarthritis in knee joint

Key facts

Sponsor
Odense University Hospital
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Decision date (initial)
2025-07-14
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Osteoarthritis in knee joint

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Odense University Hospital

Sponsor organisation
Odense University Hospital
Address
J B Winsloews Vej 4
City
Odense C
Postcode
5000
Country
Denmark

Scientific contact point

Organisation
Odense University Hospital
Contact name
Chris Halling Dreyer

Public contact point

Organisation
Odense University Hospital
Contact name
Chris Halling Dreyer

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Denmark Not authorised 112 1
Rest of world 0

Investigational sites

Denmark

1 site · Not authorised
Næstved Hospital
Orthopaedic Surgery and Traumatology, Ringstedgade 61, 4700, Næstved

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-03-31 Denmark Not acceptable
2025-07-11
2025-07-14